<p>佛罗里达州奥卡拉，2026 年 3 月 6 日（全球新闻通讯社）—— <strong>AIM ImmunoTech Inc.（纽约证券交易所：AIM）</strong> – AIM ImmunoTech Inc.（“AIM” 或 “公司”）是一家专注于其主要产品 Ampligen®（rintatolimod）研发的免疫药物公司，旨在治疗晚期胰腺癌这一致命且未满足的全球健康问题。今天宣布其先前宣布的权利发行（“权利发行”）已完成。此次权利发行的总认购金额约为 180 万美元。</p>
<p>每个权利使持有人有权以每单位 1,000 美元的认购价格购买一个单位（“单位”），该单位由一股公司的 G 系列可转换优先股（“优先股”）和 2,000 个购买公司普通股的 G 类普通股认购权证（“认购权证”）组成。</p>
<p>Maxim Group LLC 担任此次权利发行的经销商经理。</p>
<p>公司的 S-1 表格注册声明（注册号 333-292085）于 2026 年 2 月 10 日被证券交易委员会（“SEC”）宣布生效，并于 2026 年 2 月 27 日通过向 SEC 提交的招股说明书补充进行了修改。与权利发行相关的招股说明书已作为注册声明的一部分提交给 SEC，并可在 SEC 的网站上获取，网址为 https://www.sec.gov。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不会在任何州或其他司法管辖区进行这些证券的销售，在这些州或司法管辖区，任何此类要约、邀请或销售在未注册或未符合证券法的情况下都是非法的。</p>
<p><strong>关于 AIM ImmunoTech</strong></p>
<p>AIM ImmunoTech Inc.是一家专注于其主要产品 Ampligen®（rintatolimod）研发的免疫药物公司，旨在治疗晚期胰腺癌这一致命且未满足的全球健康问题。Ampligen 是一种双链 RNA 和高度选择性的 TLR3 激动剂免疫调节剂，在临床试验中显示出广谱活性。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中包含的一些声明可能是前瞻性声明，涉及多种风险和不确定性。除其他事项外，对于这些声明，公司主张根据 1995 年《私人证券诉讼改革法》对前瞻性声明的安全港保护。本新闻稿中所列的任何前瞻性声明仅在新闻稿发布之日有效。公司不承诺更新这些前瞻性声明，以反映此后发生的事件或情况。公司正在不同阶段寻求确定 Ampligen®是否对多种病毒疾病、癌症和免疫缺陷疾病的治疗有效，并在公司向 SEC 提交的报告及其新闻稿中披露其当前和预期的未来活动。这些活动可能因多种原因而发生变化。需要进行大量额外的测试和试验，以确定 Ampligen®是否对这些疾病的治疗有效。在动物模型中获得的结果不一定能预测人类的结果。需要进行人类临床试验以证明 Ampligen®在人体中的有效性。无法保证当前或计划中的临床试验将成功或产生有利的数据，试验受到许多因素的影响，包括缺乏监管批准、缺乏研究药物或赞助其他试验的机构的优先事项变化。即使这些临床试验开始，公司也无法保证临床研究将成功或产生任何有用的数据，或需要额外的资金。其中一些研究是仅提供初步数据的小规模临床试验，无法保证这些研究中的发现会被证实，或研究将产生有利的结果。无法保证未来的研究不会得出与公司在 SEC 提交的报告、公司网站和新闻稿中提到的研究结果不同的发现。在外国开展业务存在多种风险，包括在执行知识产权方面可能遇到的困难。公司无法保证其潜在的海外业务不会受到这些风险的不利影响。</p>
<p>请查看公司最新的 10-K 表格年报和后续的 10-Q 表格季度报告中的 “风险因素” 部分。其文件可在 www.aimimmuno.com 获取。公司网站上的信息不在此处引用，仅供参考。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk56Y3lOeU0zTkRjeU9UWXhJekl3TWpNeE5qUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk56Y3lOeU0zTkRjeU9UWXhJekl3TWpNeE5qUT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjJlZTE4NDgtYzBjZS00OWVjLTkyOWMtOGRjZmYzNTBiNmRiLTEwMzQ3MzUtMjAyNi0wMy0wNy1lbg==/tiny/AIM-ImmunoTech-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjJlZTE4NDgtYzBjZS00OWVjLTkyOWMtOGRjZmYzNTBiNmRiLTEwMzQ3MzUtMjAyNi0wMy0wNy1lbg==/tiny/AIM-ImmunoTech-Inc-.png"/></p>
<pre><code> 投资者关系联系方式：JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
</code></pre>

标普全球医疗股指数 ETF - iShares

美国制药 ETF - iShares

IBBQ

<p>AIM ImmunoTech Inc. 成功完成了其权利发行，筹集了约 180 万美元。每个认购允许以 1,000 美元购买一个单位，其中包括一股 G 系列可转换优先股和 2,000 个 G 类普通股认购权证。此次发行由 Maxim Group LLC 管理，证券交易委员会于 2026 年 2 月 10 日宣布注册声明生效。AIM 专注于开发 Ampligen® 用于治疗晚期胰腺癌，并强调未来临床试验及其结果的不确定性</p>

<p>OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc. (NYSE American: AIM)</strong> – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the “Rights Offering”). The Rights Offering resulted in total subscriptions of approximately $1.8 million.</p>
<div class="lb-trans"><p>佛罗里达州奥卡拉，2026 年 3 月 6 日（全球新闻通讯社）—— <strong>AIM ImmunoTech Inc.（纽约证券交易所：AIM）</strong> – AIM ImmunoTech Inc.（“AIM” 或 “公司”）是一家专注于其主要产品 Ampligen®（rintatolimod）研发的免疫药物公司，旨在治疗晚期胰腺癌这一致命且未满足的全球健康问题。今天宣布其先前宣布的权利发行（“权利发行”）已完成。此次权利发行的总认购金额约为 180 万美元。</p>
</div><p>Each right entitled the holder to purchase one unit (“Unit”), at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”).</p>
<div class="lb-trans"><p>每个权利使持有人有权以每单位 1,000 美元的认购价格购买一个单位（“单位”），该单位由一股公司的 G 系列可转换优先股（“优先股”）和 2,000 个购买公司普通股的 G 类普通股认购权证（“认购权证”）组成。</p>
</div><p>Maxim Group LLC acted as dealer-manager for the Rights Offering.</p>
<div class="lb-trans"><p>Maxim Group LLC 担任此次权利发行的经销商经理。</p>
</div><p>The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026, as modified by the prospectus supplement filed with the SEC on February 27, 2026. The prospectus relating to and describing the terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC's website at https://www.sec.gov.</p>
<div class="lb-trans"><p>公司的 S-1 表格注册声明（注册号 333-292085）于 2026 年 2 月 10 日被证券交易委员会（“SEC”）宣布生效，并于 2026 年 2 月 27 日通过向 SEC 提交的招股说明书补充进行了修改。与权利发行相关的招股说明书已作为注册声明的一部分提交给 SEC，并可在 SEC 的网站上获取，网址为 https://www.sec.gov。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不会在任何州或其他司法管辖区进行这些证券的销售，在这些州或司法管辖区，任何此类要约、邀请或销售在未注册或未符合证券法的情况下都是非法的。</p>
</div><p><strong>About AIM ImmunoTech</strong></p>
<div class="lb-trans"><p><strong>关于 AIM ImmunoTech</strong></p>
</div><p>AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.</p>
<div class="lb-trans"><p>AIM ImmunoTech Inc.是一家专注于其主要产品 Ampligen®（rintatolimod）研发的免疫药物公司，旨在治疗晚期胰腺癌这一致命且未满足的全球健康问题。Ampligen 是一种双链 RNA 和高度选择性的 TLR3 激动剂免疫调节剂，在临床试验中显示出广谱活性。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.</p>
<div class="lb-trans"><p>本新闻稿中包含的一些声明可能是前瞻性声明，涉及多种风险和不确定性。除其他事项外，对于这些声明，公司主张根据 1995 年《私人证券诉讼改革法》对前瞻性声明的安全港保护。本新闻稿中所列的任何前瞻性声明仅在新闻稿发布之日有效。公司不承诺更新这些前瞻性声明，以反映此后发生的事件或情况。公司正在不同阶段寻求确定 Ampligen®是否对多种病毒疾病、癌症和免疫缺陷疾病的治疗有效，并在公司向 SEC 提交的报告及其新闻稿中披露其当前和预期的未来活动。这些活动可能因多种原因而发生变化。需要进行大量额外的测试和试验，以确定 Ampligen®是否对这些疾病的治疗有效。在动物模型中获得的结果不一定能预测人类的结果。需要进行人类临床试验以证明 Ampligen®在人体中的有效性。无法保证当前或计划中的临床试验将成功或产生有利的数据，试验受到许多因素的影响，包括缺乏监管批准、缺乏研究药物或赞助其他试验的机构的优先事项变化。即使这些临床试验开始，公司也无法保证临床研究将成功或产生任何有用的数据，或需要额外的资金。其中一些研究是仅提供初步数据的小规模临床试验，无法保证这些研究中的发现会被证实，或研究将产生有利的结果。无法保证未来的研究不会得出与公司在 SEC 提交的报告、公司网站和新闻稿中提到的研究结果不同的发现。在外国开展业务存在多种风险，包括在执行知识产权方面可能遇到的困难。公司无法保证其潜在的海外业务不会受到这些风险的不利影响。</p>
</div><p>Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.</p>
<div class="lb-trans"><p>请查看公司最新的 10-K 表格年报和后续的 10-Q 表格季度报告中的 “风险因素” 部分。其文件可在 www.aimimmuno.com 获取。公司网站上的信息不在此处引用，仅供参考。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk56Y3lOeU0zTkRjeU9UWXhJekl3TWpNeE5qUT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NzcyNyM3NDcyOTYxIzIwMjMxNjQ="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjJlZTE4NDgtYzBjZS00OWVjLTkyOWMtOGRjZmYzNTBiNmRiLTEwMzQ3MzUtMjAyNi0wMy0wNy1lbg==/tiny/AIM-ImmunoTech-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YjJlZTE4NDgtYzBjZS00OWVjLTkyOWMtOGRjZmYzNTBiNmRiLTEwMzQ3MzUtMjAyNi0wMy0wNy1lbg==/tiny/AIM-ImmunoTech-Inc-.png"/></p>
<pre><code>IR Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
</code></pre>
<div class="lb-trans"><pre><code> 投资者关系联系方式：JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
</code></pre>
</div>

AIM ImmunoTech 宣布其配股发行已结束 | AIM 股票新闻